Crescendo and Vectra Presentations at ACR 2016 Save
Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week. These abstracts will feature research on Vectra® DA, a multi-biomarker disease activity (MDBA) assay intended to monitor and measure disease activity in patients with RA.
These presentations include:
Abstract: 2639. Title: Predicting Flare and Sustained Clinical Remission After Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score. This will be presented by Shintaro Hirata on Tuesday, Nov. 15, 2016: 9:00-11:00 a.m. ET.
Abstract: 2520. Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab. This will be presented by Heegaard Brahe on Tuesday, Nov.15, 2016: 9:00-11:00 a.m. ET.
Abstract: 535. Examination of Diurnal and Daily Variation of the Multi-biomarker Disease Activity (MBDA) Score in RA to Establish a Minimally Important Difference. This will be presented by David Chernoff on Sunday, Nov. 13, 2016: 9:00-11:00 a.m. ET.
Abstract: 1492. Biomarker-Related Risk for Myocardial Infarction and Serious Infectionsin Patients with Rheumatoid Arthritis: A Population-Based Study. THis will be presented by Jeff Curtis on Monday, Nov. 14, 2016: 9:00-11:00 a.m. ET.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.